• What Pascuala Stands For

    At Pascuala Distribution Trading Corporation, we distribute trust — not merely as a tagline, but as a standard that defines how we select, represent, and deliver every product. That trust is earned through science, consistency, and the confidence we instill in the clients who rely on our solutions.

    SAFETY

    Trust begins with safety. Every product in our catalog is carefully screened for compliance with international health regulations and Philippine safety standards. We work exclusively with manufacturers that hold KFDA, CE, ISO, and Philippine FDA certifications — ensuring each formulation is clinically safe and rigorously tested.

    CREDIBILITY

    We represent what’s proven. Pascuala collaborates only with globally recognized brands and laboratories, offering our partner physicians, dermatologists, and certified practitioners products they can confidently use in their practice. Every solution we carry reflects our commitment to clinical integrity and professional credibility.

    PERFORMANCE

    We deliver results that can be seen and felt. Whether used in aesthetic procedures, skin regeneration protocols, or non-invasive rejuvenation treatments, our products are built for visible transformation and lasting improvement. It’s not just about beauty — it’s about performance that supports your expertise and strengthens client trust.

    Next-Generation Gold-Coated Ethosome Technology for High-Efficacy Aesthetic Delivery

    EthosomePTT is an upgraded, micro-particle solution derived from ethosome, a lipid-based delivery vesicle known for its deep skin penetration. Compared to traditional liposomes, ethosomes are 3–4 times more effective at delivering active ingredients into the dermis and sub-dermal layers. The “PTT” upgrade refers to the coating of the ethosomes with colloidal gold and platinum, forming a multi-layered particle system that increases both stability and delivery efficiency.

    This upgraded structure acts as a shield against degradation caused by light or heat and provides a negatively charged surface, improving compatibility and attraction to the skin barrier.
    FEATURELIPOSOME (1960s)Ethosome (2000)Gold-Coated Ethosome (2021)
    Skin PermeabilityLowModerate-HighVery High
    Electric ChargeNoneNegativeNegative
    Light/Heat StabilityLowModerateHigh
    Layer ComplexitySingle-layerBi-layeredMulti-layered with metals
    • Niacinamide
    • Tranexamic Acid
    • Ascorbic Acid
    • Ethyl Ascorbyl Ether
    • Centella Asiatica Extract
    • Colloidal Gold and Platinum
    • Glutathione, Trehalose, and Hyaluronic Acid
    • Niacinamide
    • Centella Asiatica Extract
    • Salicylic Acid
    • Tranexamic Acid
    • Ascorbic Derivatives
    • Colloidal Gold and Platinum
    • Betaine and Methylpropanediol
    • Multi-Layered Penetration
      • Gold- and platinum-coated vesicles enhance both depth and consistency of transdermal absorption.
    • High Ingredient Stability
      • Prevents ingredient oxidation or degradation even when exposed to light or temperature fluctuations.
    • Electrical Charge Advantage
      • The negative charge of ethosomes allows better attraction to skin surfaces, improving permeability.
    • Non-Invasive Delivery System
      • Supports active ingredient delivery without the need for invasive techniques—perfect for microneedling, MTS, sonophoresis, or mesotherapy.
    • Clean, Skin-Compatible Base
      • Free from harsh solvents or harmful emulsifiers, EthosomePTT uses a water-based, dermatologically balanced vehicle.
    KEY ACTIVES (BRIGHTENING)KEY ACTIVES (ANTI-AC)
    NiacinamideNiacinamide
    Tranexamic AcidTranexamic Acid
    Ascorbic AcidSalicylic Acid
    GlutathioneCentella Asiatica Extract
    Ethyl Ascorbyl EtherColloidal Gold and Platinum

    Purified Injectable Atelocollagen for Tissue Regeneration

    Collaju is a high-purity, injectable atelocollagen tissue supplement, developed through advanced biotechnology and purified via a patented Aseptic Salt Precipitation Method. This Class 4 medical device is formulated for internal, injectable use and is indicated for both aesthetic rejuvenation and post-procedural tissue support. Each unit contains 1 mL of ready-to-use Type I collagen in liquid form, eliminating the need for mixing or rehydration.
    • Thicker collagen fiber formation
    • Greater resistance to enzymatic degradation
    • Higher retention within injected sites
    • Reduced inflammatory response
    • Facial contour restoration and wrinkle reduction
    • Acne scar revision and skin texture improvement
    • Post-surgical soft tissue reconstruction
    • Burn and trauma recovery
    • Adjunct in regenerative procedures involving bio-stimulatory agents
    • Product Name: Collaju
    • Category: Collagen Tissue Supplement
    • Packaging: 1ml/syringe × 1EA per box
    • Manufacturer: Ubiosis
    • Seller: Juventa Healthcare Co., Ltd.
    • Address: 18th Floor, 123 Digital-ro 26-gil, Guro-gu, Seoul
    • Storage: Store at room temperature (below 30°C)
    • Shelf Life: 2 years from date of manufacture
    • Certifications
      • KFDA (Korea Food & Drug Administration)
      • European CE Certified
      • Licensed by NMPA China (National Medical Products Administration)
      • ISO-compliant production

    Deoxycholic Acid Lipolysis & Adipolysis Solution

    EDGE is an advanced injectable solution indicated for the non-surgical reduction of localized fat deposits through adipolysis and lipolysis. It utilizes Deoxycholic Acid in combination with natural botanical compounds to break down fat cell membranes, enhance lipid metabolism, and promote lymphatic clearance. Clinically favored in body contouring, particularly for areas resistant to diet and exercise.
    • Deoxycholic Acid disrupts adipocyte membranes, leading to irreversible cell lysis. The released lipids are metabolized and cleared through the body’s natural excretory pathways.
    • Lipolysis: Triglycerides within the adipocytes are hydrolyzed into glycerol and free fatty acids.
    • Adipolysis: Promotes the breakdown of stored fat through metabolic stimulation.
    • Adenosine Triphosphate (ATP) supports cellular energy dynamics, facilitating tissue repair, lymphatic activation, and sustained metabolic function during and after the lipolytic process.
    INGREDIENTFUNCTION
    Deoxycholic AcidPrimary fat-dissolving agent; disrupts fat cells
    Juglans Regia (Walnut) Seed ExtractAnti-inflammatory, antioxidant
    Fucus Vesiculosus ExtractIodine-rich seaweed; enhances circulation and skin elasticity
    TyrosineAmino acid precursor; regulates metabolism
    Aesculus Hippocastanum (Horse Chestnut) ExtractReduces edema, improves venous return
    MethylpropanediolSolvent and penetration enhancer
    Methylsilanol MannuronateDerived from brown algae; promotes collagen, skin firmness
    Sodium ChlorideOsmoregulation and fluid balance
    • Sterile, water-based injectable solution
    • Stabilized with sodium and phosphate derivatives to ensure pH balance
    • Enhanced with ATP complexes for improved cellular response
    • No added preservatives; formulated for safety and bioavailability
    • Exclusively for licensed medical professionals (dermatologists, cosmetic physicians, aesthetic injectors)
    • Ideal for localized fat reduction in areas such as:
      • Submental region (double chin)
      • Upper arms
      • Abdomen
      • Flanks (love handles)
      • Thighs
    • Non-surgical alternative to liposuction and other invasive fat-reduction techniques
    • Marketed globally under export-only licensing, compliant with professional use restrictions
  • EZ-Pen is a once-weekly subcutaneous injectable combining Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor agonist activity. It is indicated for:
    • Glycemic control in Type 2 Diabetes Mellitus (T2DM)
    • Chronic weight management in obese or overweight adults
    This dual agonist mechanism enhances incretin-based therapy by achieving both superior metabolic regulation and clinically significant weight loss, with lower risk of hypoglycemia compared to traditional antidiabetic therapies.
    • Enhances glucose-dependent insulin secretion
    • Suppresses postprandial glucagon release
    • Delays gastric emptying → improved satiety and appetite suppression
    • Stimulates fat oxidation and reduces adipocyte lipogenesis
    • Modulates hypothalamic appetite pathways
    • Improves beta-cell function and preserves islet cell integrity
    • Robust HbA1c reduction (superior to GLP-1 monotherapy)
    • Sustained weight loss even in non-diabetic individuals
    • Low hypoglycemia risk (when not used with sulfonylureas/insulin)
    • Favorable impact on NAFLD, lipid profiles, and cardiovascular risk markers
    • No dose titration required for renal or hepatic impairment (but monitoring advised)
    • Adults with T2DM uncontrolled by diet, exercise, or oral agents
    • Individuals with BMI ≥30 (obesity)
    • Individuals with BMI ≥27 with weight-related comorbidities (e.g., hypertension, dyslipidemia, PCOS, NAFLD)
    • Seeking injectable alternatives to insulin
    • Experiencing plateau with oral weight loss therapies
    • Requiring cardiometabolic protection
    • Personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
    • Prior pancreatitis
    • Severe GI motility disorders (e.g., gastroparesis)
    • Active eating disorders or severe psychiatric illness
    • Known hypersensitivity to any components of the formulation
    • Pregnancy & Lactation: Avoid unless medically necessary
    • Renal/Hepatic Impairment: No dose adjustment required, but monitor volume status and renal function
    • Geriatric Use: Monitor tolerability during titration; increased GI sensitivity may occur
    • Pediatric Use: Not approved
    PROTOCOLSCHEDULEUSE CASE
    Standard (8-week)2.5mg 5mg 7.5mg 10mgGradual escalation; minimizes GI intolerance
    Flat Dose5mg weekly throughoutLong-term maintenance or mild responders
    Rapid Protocol10mg from initiationMotivated, fit adults with prior GLP-1 use
    • Subcutaneous injection (abdomen, thigh, upper arm)
    • Rotate injection sites weekly
    • Hold for 10 seconds to ensure full dose delivery
    • Missed dose: Administer within 96 hours, or skip
    • Unopened Pens: Refrigerate (2–8°C), do not freeze
    • After Opening: Store ≤30°C for up to 30 days
    • Solution Appearance: Clear and colorless only
    • Disposal: Use sharps container and follow local clinical waste protocols
    METRICTIMING
    HbA1cBaseline, then every 3-6 months
    Body WeightWeekly or biweekly
    eGFR/CreatinineBaseline and every 3-6 months (if risk)
    Lipid ProfileEvery 6-12 months
    Liver EnzymesOptional for NAFLD or hepatopathy
    Mood & GI ToleranceWeekly during tritation
    • Nausea, bloating, decreased appetite
    • Constipation or diarrhea
    • Fatigue, lightheadedness
    • Dyspepsia or early satiety
    • Reflux
    • Injection site discomfort
    • Headache or transient dizziness
    • Pancreatitis (persistent severe abdominal pain, vomiting)
    • Cholelithiasis or gallbladder inflammation
    • Severe hypoglycemia (if used with insulin or sulfonylurea)
    • Mood instability (depression, suicidal ideation)
    • Thyroid swelling or nodule (refer for evaluation)
    • Consume a light, low-fat meal 1–2 hours before
    • Maintain hydration (≥500 mL water)
    • Avoid alcohol or intense physical activity
    • Prescribe or recommend antiemetics (e.g., ondansetron) for early nausea
    • Educate on satiety, appetite reduction, and potential GI symptoms
    • Emphasize long-term adherence and expected plateauing of side effects by week 5–6
  • ← Back

    Thank you for your response. ✨